LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF 10A | Torin2 | 0.04 | uM | LJP5 | 72 | hr | 962 | 1127 | 10605 | 0.1063 | 0.0172 |
Hs 578T | Alvocidib | 0.12 | uM | LJP6 | 72 | hr | 658 | 409 | 3846 | 0.1064 | -0.0781 |
MCF7 | YM 201636 | 10.0 | uM | LJP5 | 72 | hr | 1209 | 435 | 4093 | 0.1064 | -0.2684 |
MCF 10A | PD0325901 | 3.33 | uM | LJP6 | 72 | hr | 962 | 1133 | 10605 | 0.1069 | 0.0178 |
MCF 10A | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 962 | 1137 | 10605 | 0.1072 | 0.0181 |
MCF 10A | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 962 | 1141 | 10605 | 0.1076 | 0.0186 |
MDA-MB-231 | SNS-032 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 489 | 4513 | 0.1083 | -0.2279 |
MCF7 | AT-7519 | 10.0 | uM | LJP6 | 72 | hr | 1209 | 443 | 4093 | 0.1084 | -0.2656 |
Hs 578T | Alvocidib | 3.33 | uM | LJP6 | 72 | hr | 658 | 419 | 3846 | 0.1090 | -0.0749 |
MCF 10A | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 962 | 1162 | 10605 | 0.1096 | 0.0207 |
MDA-MB-231 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1235 | 496 | 4513 | 0.1100 | -0.2257 |
Hs 578T | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 658 | 423 | 3846 | 0.1102 | -0.0736 |
MDA-MB-231 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 497 | 4513 | 0.1102 | -0.2254 |
Hs 578T | Alvocidib | 1.11 | uM | LJP6 | 72 | hr | 658 | 424 | 3846 | 0.1102 | -0.0735 |
MDA-MB-231 | WZ3105 | 0.04 | uM | LJP5 | 72 | hr | 1235 | 498 | 4513 | 0.1103 | -0.2251 |
Hs 578T | Geldanamycin | 10.0 | uM | LJP6 | 72 | hr | 658 | 425 | 3846 | 0.1105 | -0.0731 |
MDA-MB-231 | CGP60474 | 0.12 | uM | LJP6 | 72 | hr | 1235 | 506 | 4513 | 0.1121 | -0.2227 |
Hs 578T | WZ3105 | 0.12 | uM | LJP5 | 72 | hr | 658 | 431 | 3846 | 0.1122 | -0.0711 |
Hs 578T | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 658 | 431 | 3846 | 0.1122 | -0.0711 |
MDA-MB-231 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1235 | 506 | 4513 | 0.1123 | -0.2225 |
MCF7 | JNK-9L | 1.11 | uM | LJP6 | 72 | hr | 1209 | 460 | 4093 | 0.1125 | -0.2598 |
MCF 10A | XMD11-50 | 10.0 | uM | LJP6 | 72 | hr | 962 | 1194 | 10605 | 0.1127 | 0.0241 |
Hs 578T | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 658 | 435 | 3846 | 0.1132 | -0.0699 |
Hs 578T | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 658 | 436 | 3846 | 0.1134 | -0.0697 |
Hs 578T | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 658 | 436 | 3846 | 0.1135 | -0.0696 |